Track topics on Twitter Track topics that are important to you
Dr Ravaud speaks with ecancertv at ESMO 2016 about results from a one-year trial of sunitinib vs placebo for post-nephrectomy high-risk renal cancer patients. This phase III trial found a longer di...
Patients with renal cell carcinoma at high risk for recurrence had prolonged disease-free survival when treated with sunitinib compared with placebo.
* Cabozantinib met primary endpoint of improving progression-free survival as compared to Sunitinib
Patients with metastatic renal cell carcinoma treated with sunitinib often experience treatment-related hypertension and require rigorous blood pressure control.
Patients with renal cancer and a high risk for recurrence after nephrectomy may benefit from adjuvant sunitinib, which showed a disease-free survival benefit in a phase 3 trial. Medscape Medical New...
Pfizer has unveiled results from the Phase 3 S-TRAC clinical trial (Sunitinib Trial as Adjuvant Treatment of Renal Cancer) investigating SUTENT (sunitinib) as adjuvant therapy.
Monday, October 10th 2016 at 6:15am UTC Late-breaking data to be presented at the ESMO 2016 Congress and Published in The New England Journal of Medicine NEW YORK–(BUSINESS WIRE)– Pfizer I...
Breaks from active sunitinib treatment for patients with treatment-naive metastatic renal cell carcinoma may be possible without effecting clinical efficacy.
Sunitinib is an oral tyrosine kinase inhibitor used for cancer treatment. Patients treated with sunitinib are at higher bleeding risk. As tyrosine kinases are essential for platelet signalling, the ef...
Molecular targeted therapy is a standard treatment for patients with advanced renal cell carcinoma (RCC). Sunitinib is one of the most common molecular-targeted drugs for metastatic RCC. Molecular mec...
Sunitinib is an orally delivered tyrosine kinase inhibitor that exhibits antiangiogenic effects. FDA has approved sunitinib for the treatment of metastatic renal cell carcinoma. However, its efficacy ...
The most efficient sequence of targeted agents for metastatic renal cell carcinoma patients has yet to be identified. Whether the sequence of sorafenib and sunitinib really matters is controversial an...
Sunitinib is a protein tyrosine kinase (PTK) inhibitor that has immune-modulating properties. In this context, peripheral blood mononuclear cells (PBMC), mainly constituted by lymphocytes, could be a ...